


## SUPPLEMENTARY FIGURE LEGENDS


**Figure S1: Histopathology in FSHD-like mice.**

Photomicrographs of tibialis anterior muscle in each group of mice: ACTA1-MCM/+ with TMX (control), ACTA1-MCM, FLExD/+ no TMX (mild) and ACTA1-MCM, FLExD/+ 7 days post-TMX (SD7). Hematoxylin and Eosin staining (a-c), DUX4 immunostaining co-localized with DAPI (d-f) or alone (g-i). Representative images are shown based on n=3-4 mice per group. White arrows indicate representative DUX4 positive myonuclei.



**Figure S2: Analysis of male and female FSHD-like mice.**

Male and female mice used in Figure 4 were assessed for maximum tetanus (**a.**), and cross-sectional muscle area normalized specific tetanus (**b.**) and analyzed separately by sex. IL-6 levels in the serum (**c.**) and gastrocnemius muscle (**d.**) in each group of mice: Control, blue (n=6 in serum, n=10 in muscle), Mild, green (n=8 in serum, n=10 in muscle) and SD7 (n=6 in serum, n=10 in muscle) were separated by sex. Significance: \* p<0.05, \*\* p<0.01.



**Supplementary Table 1: Correlations between serum cytokine levels and clinical scores.**

Spearman's correlation coefficient (R) and False Discovery Rate (FDR) determination for the indicated cytokines and clinical scores in all patients, males and females.

MMT sum score						
	All		Males		Females	
	R	FDR	R	FDR	R	FDR
GM-CSF	0·00	1·00	-0·22	0·20	0·30	0·12
IFN-γ	-0·20	0·13	-0·17	0·34	-0·06	0·84
IL-5	0·03	0·94	0·01	1·00	0·03	0·99
IL-6	<b>-0·38</b>	<b>2·97E-04</b>	<b>-0·46</b>	<b>2·72E-03</b>	-0·33	0·10
IL-7	-0·07	0·70	-0·15	0·38	0·08	0·80
IL-8	-0·09	0·60	-0·23	0·20	0·01	0·99
IL-10	0·02	0·95	-0·29	0·12	0·24	0·23
IL-12p40	-0·21	0·1	-0·24	0·20	-0·12	0·68
IL-15	-0·03	0·94	-0·17	0·34	0·16	0·55
IL-16	-0·11	0·51	-0·23	0·20	-0·12	0·68
IL-17	-0·14	0·37	0·00	1·00	-0·15	0·56
TNF-α	-0·15	0·30	-0·25	0·20	-0·08	0·80
TNF-β	0·10	0·57	-0·03	1·00	0·32	0·10
VEGF	0·05	0·83	0·07	0·79	0·01	0·99

Brooke score						
	All		Males		Females	
	R	FDR	R	FDR	R	FDR
GM-CSF	0·06	0·70	0·27	0·16	-0·19	0·38
IFN-γ	0·10	0·50	0·15	0·39	0·02	0·95
IL-5	-0·05	0·71	0·05	0·83	-0·19	0·38
IL-6	<b>0·31</b>	<b>6·82E-03</b>	<b>0·30</b>	<b>1·27E-01</b>	0·32	0·12
IL-7	-0·07	0·70	0·09	0·60	-0·26	0·19
IL-8	0·14	0·30	0·21	0·31	0·09	0·73
IL-10	0·10	0·50	0·16	0·37	0·05	0·90
IL-12p40	0·26	0·03	0·28	0·14	0·23	0·28
IL-15	0·10	0·50	0·17	0·37	-0·02	0·95
IL-16	0·16	0·24	0·18	0·37	0·16	0·49
IL-17	0·02	0·93	-0·03	0·87	0·05	0·90
TNF-α	0·19	0·14	0·24	0·21	0·13	0·53
TNF-β	-0·03	0·86	0·16	0·37	-0·27	0·19
VEGF	-0·15	0·29	-0·16	0·37	-0·13	0·53

Vignos score						
	All		Males		Females	
	R	FDR	R	FDR	R	FDR
<b>GM-CSF</b>	-0.03	0.90	0.14	0.43	-0.23	0.46
<b>IFN-γ</b>	0.29	0.01	0.26	0.12	0.19	0.56
<b>IL-5</b>	0.00	1.00	0.04	0.83	-0.06	0.96
<b>IL-6</b>	<b>0.47</b>	<b>3.29E-06</b>	<b>0.56</b>	<b>1.08E-04</b>	<b>0.38</b>	<b>0.03</b>
<b>IL-7</b>	0.05	0.86	0.10	0.57	-0.04	0.96
<b>IL-8</b>	0.17	0.19	0.26	0.12	0.12	0.75
<b>IL-10</b>	0.03	0.90	0.29	0.10	-0.16	0.57
<b>IL-12p40</b>	0.18	0.19	0.23	0.17	0.07	0.96
<b>IL-15</b>	0.15	0.25	0.29	0.10	-0.05	0.96
<b>IL-16</b>	0.12	0.36	0.26	0.12	0.02	0.96
<b>IL-17</b>	0.16	0.20	0.07	0.72	0.19	0.56
<b>TNF-α</b>	0.25	0.04	0.31	0.09	0.17	0.57
<b>TNF-β</b>	0.02	0.96	0.14	0.43	-0.14	0.62
<b>VEGF</b>	-0.10	0.51	-0.19	0.25	0.02	0.96

CSS						
	All		Males		Females	
	R	FDR	R	FDR	R	FDR
<b>GM-CSF</b>	0.03	0.92	0.21	0.26	-0.18	0.60
<b>IFN-γ</b>	0.24	0.05	0.31	0.09	0.07	0.91
<b>IL-5</b>	0.03	0.92	0.08	0.66	0.00	1.00
<b>IL-6</b>	<b>0.48</b>	<b>1.26E-06</b>	<b>0.59</b>	<b>2.19E-05</b>	<b>0.36</b>	<b>0.05</b>
<b>IL-7</b>	0.09	0.65	0.14	0.50	-0.03	0.93
<b>IL-8</b>	0.09	0.65	0.17	0.38	0.04	0.92
<b>IL-10</b>	0.07	0.76	0.28	0.12	-0.09	0.85
<b>IL-12p40</b>	0.22	0.07	0.23	0.21	0.14	0.64
<b>IL-15</b>	0.05	0.81	0.12	0.56	-0.06	0.91
<b>IL-16</b>	0.08	0.67	0.17	0.38	0.05	0.91
<b>IL-17</b>	0.22	0.07	0.09	0.66	0.25	0.27
<b>TNF-α</b>	0.19	0.12	0.25	0.17	0.15	0.64
<b>TNF-β</b>	-0.01	1.00	0.07	0.72	-0.15	0.64
<b>VEGF</b>	0.00	1.00	-0.05	0.78	0.10	0.82

Age-corrected CSS						
	All		Males		Females	
	R	FDR	R	FDR	R	FDR
<b>GM-CSF</b>	0.08	0.62	0.20	0.29	-0.02	0.95
<b>IFN-γ</b>	0.07	0.64	0.29	0.11	-0.21	0.39
<b>IL-5</b>	-0.08	0.62	0.06	0.78	-0.21	0.39
<b>IL-6</b>	<b>0.07</b>	<b>6.24E-01</b>	<b>0.31</b>	<b>9.17E-02</b>	-0.18	0.47
<b>IL-7</b>	0.12	0.61	0.14	0.49	0.09	0.78
<b>IL-8</b>	-0.10	0.62	0.00	1.00	-0.18	0.47
<b>IL-10</b>	0.18	0.26	0.31	0.09	0.14	0.61
<b>IL-12p40</b>	0.12	0.61	0.12	0.58	0.07	0.85
<b>IL-15</b>	-0.04	0.74	0.10	0.69	-0.24	0.37
<b>IL-16</b>	0.11	0.61	0.28	0.11	-0.02	0.95
<b>IL-17</b>	-0.07	0.62	-0.15	0.49	-0.05	0.91
<b>TNF-α</b>	0.02	0.92	0.25	0.15	-0.27	0.37
<b>TNF-β</b>	-0.06	0.69	0.05	0.78	-0.15	0.59
<b>VEGF</b>	-0.09	0.62	-0.07	0.78	-0.09	0.78

**Supplementary Table 2: Control demographics**

	All (n=50)	Males (n=25)	Females (n=25)	Males vs. Females p-value
<b>Age at Exam</b>	54.8 ± 6.4	55.1 ± 7.1	54.6 ± 5.7	P=0.88